Fulcrum Therapeutics (FULC) Preferred Dividend Payments (2018 - 2019)
Fulcrum Therapeutics (FULC) posted quarterly Preferred Dividend Payments of $796000.0 for Q3 2019, down 57.16% year-over-year from $1.9 million in Q3 2018, and down 75.81% quarter-over-quarter from $3.3 million in Q2 2019.
Fulcrum Therapeutics (FULC) Preferred Dividend Payments (2018 - 2019) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Preferred Dividend Payments for 2 consecutive years, with $796000.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Preferred Dividend Payments fell 57.16% year-over-year to $796000.0; the TTM figure through Dec 2019 stood at $7.1 million (changed N/A YoY), while the FY2019 annual figure was $7.1 million, up 8.68% from the prior year.
- Preferred Dividend Payments retreated to $796000.0 in Q3 2019 per FULC's latest filing, from $3.3 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $3.3 million in Q2 2019 and bottomed at $796000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 796,000.00 |
| Jun 30, 2019 | 3.29 Mn |
| Mar 31, 2019 | 3.04 Mn |
| Dec 31, 2018 | 2.82 Mn |
| Sep 30, 2018 | 1.86 Mn |
| Jun 30, 2018 | 1.05 Mn |